New hope for cancer patients with dangerous low immune cell counts
NCT ID NCT06956547
First seen Oct 31, 2025 · Last updated Jun 11, 2026 · Updated 25 times
Summary
This study provides expanded access to an experimental drug called nogapendekin-alfa inbakicept for adults with low lymphocyte counts (lymphopenia) caused by chemotherapy, immunotherapy, or radiation therapy. The goal is to restore and maintain healthy lymphocyte levels. Participants must have solid tumors that have progressed after standard treatments and cannot join other clinical trials using this drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chan Soon - Shiong Institute for Medicine
AVAILABLEEl Segundo, California, 90245, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.